11 – 20 of 135
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
Vocational awe is (not) enough : Learnings from early adopters of serious illness communication
- Contribution to journal › Article
-
Mark
Brentuximab vedotin monotherapy is a feasible and effective treatment for older patients with classical Hodgkin lymphoma unsuitable for curative chemotherapy : Results from the prospective GHSG–NLG phase II BVB trial
- Contribution to journal › Letter
-
Mark
Serious illness conversations and quality of end-of-life care in patients with hematological malignancies-a retrospective quality improvement study
- Contribution to journal › Article
-
Mark
Implementation of standard of care CAR-T-cell treatment for patients with aggressive B-cell lymphoma and acute lymphoblastic leukemia in Sweden : LYMPHOMA
- Contribution to journal › Letter
-
Mark
Lymphomas : ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
- Contribution to journal › Article
-
Mark
Inter-reader agreement of quantitative FDG PET/CT biomarkers in lymphoma : a multicentre evaluation of MTV, TLG and Dmax
- Contribution to journal › Article
-
Mark
Limited stage mantle cell lymphoma : A real-world study of primary treatment and prognosis in Sweden 2006–2018
- Contribution to journal › Letter
-
Mark
Disease progression more than 6 years after treatment impacts overall survival in mantle cell lymphoma
(2025) In International Journal of Cancer
- Contribution to journal › Article
-
Mark
Peripheral T- and natural killer-cell lymphomas : ESMO–EHA Clinical Practice Guideline for diagnosis, treatment and follow-up ☆
- Contribution to journal › Article
-
Mark
Real-world outcomes with ibrutinib in relapsed or refractory mantle cell lymphoma : a Danish population-based study
- Contribution to journal › Article
